Diabetes News and Research

Latest Diabetes News and Research

Viewpoints: 'Accepted wisdom' about cutting entitlements disputed; Profit motive doesn't lead to good health care

It has become accepted economic wisdom that the only way to get control over America's looming budget deficits is to "reform entitlements." The accepted wisdom is wrong. ... Medicare and Medicaid costs are projected to soar. But here again, look closely and you'll see neither is really the problem. The underlying problem is the soaring cost of health care overall, combined with the aging of the boomer generation.

9 Jan 2013

Metabolic stress can increase onset of atrial fibrillation

Researchers have found new evidence that metabolic stress can increase the onset of atrial arrhythmias, such as atrial fibrillation (AF), a common heart condition that causes an irregular and often abnormally fast heart rate.

9 Jan 2013

Concern regarding cefixime failure rate in gonorrhea patients

Results from a Canadian study add to those of prior studies suggesting that resistance of Neisseria gonorrhoeae to the cephalosporin antibiotic cefixime is increasing worldwide.

9 Jan 2013

Oxaliplatin and bevacizumab disappoint for rectal cancer

The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.

9 Jan 2013

Tibial artery calcification predicts foot ulceration

Tibial artery calcification is a significant risk factor for foot ulcers in patients with Type 2 diabetes, research suggests.

9 Jan 2013

New scoring system can help clinicians better identify non-ICU patients at risk for GI bleeding

Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.

9 Jan 2013

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Boehringer Ingelheim and Eli Lilly and Company today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor being studied for treatment of patients with Type 2 Diabetes (T2D).

9 Jan 2013

Tunisian women more likely to suffer from obesity than male compatriots

Men and women in Tunisia are not equal before the scales. Tunisian women are three times as likely to suffer from obesity as their male compatriots.

9 Jan 2013

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801.

9 Jan 2013

Study demonstrates effects of obesity on 'Taupathies'

In France, more than 860,000 people suffer from Alzheimer's disease and related disorders, making them the largest cause of age-related loss of intellectual function. Cognitive impairments observed in Alzheimer's disease result from the accumulation of abnormal tau proteins in nerve cells undergoing degeneration . We know that obesity, a major risk factor in the development of insulin resistance and type 2 diabetes, increases the risk of dementia during the aging process.

9 Jan 2013

Asthma linked to pulmonary embolism risk

Patients with asthma have an increased risk for pulmonary embolism, show Dutch findings.

8 Jan 2013

Cost-ineffective drug prescribing practices revealed

Around four in 10 physicians prescribe a brand-name drug due to a patient request, when a generic equivalent is available, find researchers.

8 Jan 2013

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

8 Jan 2013

New study finds that adults with diabetes in Ontario get fewer government-funded eye exams

A new study has found that adults with diabetes in Ontario are getting significantly fewer government-funded eye exams than they were a decade ago, a key component of high-quality diabetes care essential to preventing diabetes-related eye complications.

8 Jan 2013